medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 2

<< Back Next >>

Ann Hepatol 2012; 11 (2)

Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1

Umgelter A, Wagner KS, Reindl W, Luppa PB, Geisler F, Huber W, Schmid RM

Language: English
References: 24
Page: 232-239
PDF size: 92.06 Kb.


ABSTRACT

Introduction. Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension. This uncontrolled interventional pilot study examines the hemodynamic and renal effects of large volume plasma expansion in HRS I. Material and methods. 14 cirrhotic patients (8 m, 6 f, age 60 (58-65) years) with HRS I received large volume plasma expansion with up to 400 mL of 20% human albumin solution per 12 over 48 h under hemodynamic monitoring by transpulmonary thermodilution. Creatinine clearances (ClCreat) were calculated for 12-h periods. Plasma expansion was withheld if criteria of volume overload [Extravascular lung Water Index (ELWI) › 9 mL/kg or Global End-Diastolic Volume Index (GEDI) › 820 mL/m2] were met. Paracentesis was performed according to clinical necessity and treatment continued for 48 h thereafter. Serum creatinine values were observed for 12 days. Results. Patients received 1.6 (1.5-2.0) g of albumin per kg bodyweight and day for 48 to 96 h. During the treatment period, GEDVI [724 (643-751) mL/m2 vs. 565 (488-719) mL/m2; p = 0.001], cardiac index (CI) [4.9 (4.1-6.15) L/min/m2 vs. 3.9 (3.4-5.0) L /min/m2; p = 0.033], urinary output [25 (17-69) mL/h vs. 17 (8-39) mL/h; p = 0.016) and ClCreat [20 (15-47) vs. 12 (6-17); p = 0.006] increased whereas systemic vascular resistance index (SVRI), plasma renin activity (PRA) and plasma aldosterone were significantly reduced. At 48 h there were two complete responses (serum creatinine ‹ 133 µ mol/L) and on day 12, 8 patients had a complete response. Conclusion. HRS I may respond to large volume plasma expansion with or without paracentesis.


REFERENCES

  1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.

  2. Henriksen JH, Bendtsen F, Sørensen TI, et al. Reduced central blood volume in cirrhosis. Gastroenterology 1989; 97:1506-13.

  3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal Syndrome. Lancet 2003; 362: 1819-27.

  4. Stadlbauer V, Wright GA, Banaji M, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008; 134: 111-9.

  5. Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004; 40: 159-61.

  6. Garcia-Compean D, Zacarias Villarreal J, Bahena Cuevas H, Garcia Cantu DA, Estrella M, Garza Tamez E, Valadez Castillo R, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver 1993; 13: 233-8.

  7. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J.: Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.

  8. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.

  9. Brinch K, Moller S, Bendtsen F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatology 2003; 39: 24-31.

  10. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48(3): 1002-10.

  11. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, Milicua JM, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42: 439-47.

  12. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.

  13. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del- Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-9.

  14. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. J Hepatology 2007; 47: 499-505.

  15. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.

  16. Dobre M, Demirjian S, Sehgal AR, et al. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 2011; 43: 175-84.

  17. Salerno F, Gerbes A, Ginès P, et al. Definition, diagnosis and treatment of hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007; 56: 1310-8.

  18. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. In: J Hepatol 2010:10.1016/j.jhep.2010. 1011.1020.

  19. Nazar A, Pereira GH, Guevara MN, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010; 51: 219-26.

  20. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Alimentary Pharmacology & Therapeutics 2006; 24: 935-44.

  21. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and he patorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.

  22. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.

  23. Lim JK, Groszmann RJ. Vasoconstrictor therapy for the hepatorenal syndrome. Gastroenterology 2008; 134: 1608-11.

  24. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011 [Epub ahead of print].




2020     |     www.medigraphic.com